Nintedanib in the treatment of IPF: does lung function rebound after drug withdrawal?

Nintedanib (Nintedanib) is an anti-fibrosis targeted drug approved by the FDA and EMA for the treatment of idiopathic pulmonary fibrosis (IPF). It mainly inhibits a variety of tyrosine kinases, including VEGFR, FGFR and PDGFR, to prevent abnormal activation and proliferation of fibroblasts, thereby delaying the fibrosis process of lung tissue. After using this drug for a period of time, many IPF patients consider stopping taking the drug due to side effects, financial burden or other personal reasons. At this time, the question they are most concerned about is: "If the drug is stopped, will the lung function rebound?"

Judging from current international guidelines and clinical practice data, the main role of nintedanib is to delay the decline of lung function, rather than to reverse pulmonary fibrosis that has already occurred. The drug does not completely cure IPF, so once the drug is stopped, the natural progression of the disease itself may be "unchained." The so-called "rebound" is actually a manifestation of an accelerated decline in lung function. This change may become very obvious in a short period of time in some patients. For example, some patients may experience worsening dyspnea, changes in lung imaging, or a significant decrease in exercise tolerance weeks or months after stopping the drug. This clinical manifestation is often mistaken for a resurgence of side effects caused by the drug, but is actually a true reflection of the rapid progression of the disease.

The long-term safety of nintedanib has been confirmed by multiple overseas studies. Although it may cause side effects such as diarrhea and abnormal liver function, the vast majority of patients can continue to use the drug through individualized dose adjustment, dietary management and auxiliary treatment. For patients who are considering discontinuing medication, it is recommended not to interrupt medication without authorization. Instead, they should evaluate the risks and benefits of discontinuing medication under the guidance of a professional doctor, and explore other more suitable treatment options.

Reference materials:https://en.wikipedia.org/wiki/Nintedanib